BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26046408)

  • 21. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
    JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
    Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
    PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
    Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
    Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
    Diabetes Res Clin Pract; 2013 Dec; 102(3):233-41. PubMed ID: 24183258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).
    Alashkham A; Paterson C; Windsor P; Struthers A; Rauchhaus P; Nabi G
    Clin Genitourin Cancer; 2016 Oct; 14(5):398-405. PubMed ID: 27053500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
    Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
    Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
    Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Dos Santos TM; Mazza L; Feldman A; D'Andréa Saba Arruda G; de Albuquerque DC; Camiletti AS; de Sousa AS; de Paula TC; Giusti KGD; Domiciano RAM; Noya-Rabelo MM; Hamilton AM; Loures VA; Dionísio RM; Furquim TAB; De Luca FA; Dos Santos Sousa ÍB; Bandeira BS; Zukowski CN; de Oliveira RGG; Ribeiro NB; de Moraes JL; Petriz JLF; Pimentel AM; Miranda JS; de Jesus Abufaiad BE; Gibson CM; Granger CB; Alexander JH; de Souza OF;
    JAMA; 2021 Jan; 325(3):254-264. PubMed ID: 33464336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: A propensity-matched study in the community.
    Egido JJ; Gomez R; Romero SP; Andrey JL; Ramirez D; Rodriguez A; Pedrosa MJ; Gomez F
    Int J Clin Pract; 2019 Jun; 73(6):e13317. PubMed ID: 30694579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).
    Hsieh MS; How CK; Hsieh VC; Chen PC
    Shock; 2020 Apr; 53(4):407-415. PubMed ID: 31135703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
    Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
    González-Cambeiro MC; López-López A; Abu-Assi E; Raposeiras-Roubín S; Peña-Gil C; García-Acuña J; González-Juanatey R
    Rev Port Cardiol; 2016 Dec; 35(12):645-653. PubMed ID: 27865680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
    Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.
    Walker AM; Liang C; Clifford CR; Parker C; Feldman A
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):348-56. PubMed ID: 24375940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease.
    Juneja A; Zia S; Abeysekara A; Shams S; Singh K; Schor J; Deitch J
    Vascul Pharmacol; 2020 Aug; 131():106764. PubMed ID: 32629143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of atrial fibrillation in patients with coeliac disease: a nationwide cohort study.
    Emilsson L; Smith JG; West J; Melander O; Ludvigsson JF
    Eur Heart J; 2011 Oct; 32(19):2430-7. PubMed ID: 21653560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ; Chu H; Ou SM; Chen YT
    Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertension Treatment Modality and Suicide Risk Among Veterans in Veterans Health Administration Care From 2015 to 2017.
    Dent KR; Griffin CA; McCarthy JF; Katz IR
    JAMA Netw Open; 2020 Oct; 3(10):e2020330. PubMed ID: 33044550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.